The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells
| Autor: | Yasmine Radwan, Dominika Bila, Kirill A. Afonin, Martin Panigaj, Marina A. Dobrovolskaia |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_treatment
Pharmaceutical Science Organic chemistry 02 engineering and technology Computational biology Review Analytical Chemistry 03 medical and health sciences Immune system complement activation-related pseudoallergy QD241-441 nucleic acid nanoparticles (NANPs) Nucleic Acids Drug Discovery medicine Animals Humans Physical and Theoretical Chemistry Receptor 030304 developmental biology 0303 health sciences Chemistry Pattern recognition receptor cytokine storm syndrome Translation (biology) Immunotherapy Cpg oligonucleotides 021001 nanoscience & nanotechnology Complement system Nanostructures Toll-like receptors immunorecognition Chemistry (miscellaneous) Immune System Nucleic acid Molecular Medicine Cytokines Nanoparticles 0210 nano-technology immunoreaction |
| Zdroj: | Molecules, Vol 26, Iss 4231, p 4231 (2021) Molecules |
| ISSN: | 1420-3049 |
| Popis: | The relatively straightforward methods of designing and assembling various functional nucleic acids into nanoparticles offer advantages for applications in diverse diagnostic and therapeutic approaches. However, due to the novelty of this approach, nucleic acid nanoparticles (NANPs) are not yet used in the clinic. The immune recognition of NANPs is among the areas of preclinical investigation aimed at enabling the translation of these novel materials into clinical settings. NANPs’ interactions with the complement system, coagulation systems, and immune cells are essential components of their preclinical safety portfolio. It has been established that NANPs’ physicochemical properties—composition, shape, and size—determine their interactions with immune cells (primarily blood plasmacytoid dendritic cells and monocytes), enable recognition by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs), and mediate the subsequent cytokine response. However, unlike traditional therapeutic nucleic acids (e.g., CpG oligonucleotides), NANPs do not trigger a cytokine response unless they are delivered into the cells using a carrier. Recently, it was discovered that the type of carrier provides an additional tool for regulating both the spectrum and the magnitude of the cytokine response to NANPs. Herein, we review the current knowledge of NANPs’ interactions with various components of the immune system to emphasize the unique properties of these nanomaterials and highlight opportunities for their use in vaccines and immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|